About Epic
About Epi-C
Human desease treatment
Epi-c is a ‘disease-oriented’, Biotech drug discovery company, focused on molecules, toxicology and epigenetics for cancer therapy and prevention.
Epigenetic drugs represent an innovative and emerging market that offers new opportunities in human diseases treatment.
Epi-C’s goal is to modulate the complex mechanism of epigenetic regulation, forcing cancer cells to restore physiological activity and die either for senescence or programmed death (apoptosis). In addition, since epigenetic mechanism(s) modulate both the induction and the interference with cell death, Epi-C’s molecules might be applied to degenerative diseases, as well as chronic, metabolic alterations.
Why do they choose our service and our product?
Epi-C offers the customer standardized in vitro screening services of libraries of compounds on epigenetic targets HDAC1, HDAC4, HDAC6, SIRT1, P300 and KDM, involved in the onset of tumors and metabolic disorders. This service allows the customer to quickly characterize new drugs.
Epi-C also offers the possibility to purchase standardized kits, useful for obtaining home-made results. Between these KDM4A InhibitorEnzymaticAssay KIT (Cod. 2016-001), allows the rapid identification of new KDM4A inhibitors, with a sensitivity in the micro and nanomolar.
Unlike the other products sold on the market today, our kit is less expensive, fast and easy to use.
What is the focus that strongly characterizes us?
Epigenetic targets represent an innovative and emerging market given their involvement in the development and progression of cancer, degenerative diseases and chronic metabolic alterations. The identification of an epi-drug that acts in a target-specific manner is part of the increasingly promising concept of “precision medicine”, offering new treatment opportunities.
The goal of Epi-C is to study and modulate the complex underlying epigenetic regulation, inducing cells to restore their correct physiological state.
Over the years, Epi-C has developed a set of epigenome-based biomarkers to discriminate subgroups of acute leukemia with poor prognosis (pending); new epidrugs (patent pending) and innovative therapeutic approaches to reverse tumors with poor prognosis; kit of enzymatic assays for the identification of new epigenetic molecules.
Epi-C’s first drugs have shown a 90% reduction of the tumor mass
on immunosuppressed mice.
Epigenome-based set of biomarkers for discriminating subsets of acute leukemia with poor prognosis (under patenting). New epidrugs (under patenting) and innovative therapeutic approaches to revert poor-prognosis cancers Improvements of bio-statistical analyses Compounds characterization and enzymatic assays.
EPI-C MISSION
Human Health
Epi-C’s goal is to modulate the complex mechanism of epigenetic regulation, forcing cancer cells to restore physiological activity and die either for senescence or programmed death (apoptosis). In addition , since epigenetic mechanism(s) modulate both the induction and the interference with cell death, Epi-C’s molecules might be applied to degenerative diseases, as well as chronic, metabolic alterations.
Our values
Bold vision
Cohesion and Collaboration
Service
More information ?
Donate Now to research for the human health